Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2010 08:05 ET | Source: Arcadia Capital Advisors, LLC

Arcadia Capital Advisors Recommends Accelrys Inc. Return Cash to Shareholders

NEW YORK, Sept. 27, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC ("Arcadia"), a shareholder of Accelrys, Inc., ("Accelrys", or the "Company") (Nasdaq:ACCL), and its managing director,...
September 07, 2010 08:00 ET | Source: Arcadia Capital Advisors, LLC

Arcadia Capital Advisors Urges Cypress Bioscience to Explore Alternatives, Not Acquisitions

NEW YORK, Sept. 7, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC ("Arcadia"), a shareholder of Cypress Bioscience Inc. ("Cypress" or the "Company"), and its managing director, Richard S....
May 26, 2010 08:00 ET | Source: Arcadia Capital Advisors, LLC

Arcadia Capital Advisors Urges Symyx Board of Directors to Consider Competing Cash Bids

NEW YORK, May 26, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC ("Arcadia") and its managing director, Richard S. Rofe ("Rofe"), a shareholder of Symyx Technologies ("Symyx"), reported that...
May 24, 2010 17:47 ET | Source: Arcadia Capital Advisors, LLC

Arcadia Capital Advisors Managing Director Richard S. Rofe Announces Expiration of Tender Offer for CPEX Pharmaceuticals

NEW YORK, May 24, 2010 (GLOBE NEWSWIRE) -- Richard Rofe today announced the expiration of the previously-announced tender offer (the "Offer") for all outstanding common shares of CPEX Pharmaceuticals,...
May 06, 2010 19:15 ET | Source: Arcadia Capital Advisors, LLC

Arcadia Capital Advisors Managing Director Richard S. Rofe Comments on CPEX Pharmaceuticals Board Recommended Rejection of Tender Offer

NEW YORK, May 6, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC, Managing Director Richard S. Rofe, issued a statement in response to a press release issued this morning by CPEX...
May 06, 2010 18:09 ET | Source: Arcadia Capital Advisors, LLC

Arcadia Capital Advisors Managing Director Richard S. Rofe Comments on CPEX Pharmaceuticals Board Recommended Rejection of Tender Offer

NEW YORK, May 6, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC, Managing Director Richard S. Rofe, issued a statement in response to a press release issued this morning by CPEX...
April 23, 2010 07:00 ET | Source: Arcadia Capital Advisors, LLC

Richard S. Rofe Announces Commencement of All-Cash $16.00 Per Share Tender Offer for CPEX Pharmaceuticals Through RSR Acquisition Co., a Wholly-Owned Subsidiary of Shelter Bay Holdings, LLC

NEW YORK, April 23, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors Managing Director Richard Rofé announced today that he has commenced a $16.00 per share all-cash tender offer for CPEX...
April 13, 2010 11:48 ET | Source: Arcadia Capital Advisors, LLC

Arcadia Capital Advisors Managing Director Richard S. Rofe Responds to CPEX Management's Most Recent Statements

Agrees With Long Overdue Decision to Terminate Nasulin Program on Which Arcadia Believes CPEX Management Misapplied $17 Million in Failed R&D in First Eighteen Months as Public Company CPEX...
April 05, 2010 18:14 ET | Source: Arcadia Capital Advisors, LLC

Arcadia Capital Advisors Managing Director Richard S. Rofe Comments on CPEX Pharmaceuticals' Recent Partner News

News Reinforces Premise That Current CPEX Strategy Misguided Rofé Questions Management Strategy to Continue Pursuit of Internal Drug Development NEW YORK, April 5, 2010 (GLOBE NEWSWIRE) --...
March 19, 2010 08:55 ET | Source: Arcadia Capital Advisors, LLC

Arcadia Capital Advisors Managing Director Richard S. Rofe Comments on CPEX Pharmaceuticals' Failed Nasulin Phase 2a Trial

Reiterates Need for CPEX Board to Exercise Independence and Fiduciary Duty Raises Issue of Possible Fraud Being Perpetrated on CPEX Shareholders NEW YORK, March 19, 2010 (GLOBE NEWSWIRE) --...